Vitamin D3 Deficiency Differentially Affects Functional and Disease Outcomes in the G93A Mouse Model of Amyotrophic Lateral Sclerosis by Solomon, Jesse A. et al.
Vitamin D3 Deficiency Differentially Affects Functional
and Disease Outcomes in the G93A Mouse Model of
Amyotrophic Lateral Sclerosis
Jesse A. Solomon
1,2, Alexandro Gianforcaro
1,2, Mazen J. Hamadeh
1,2,3*
1School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, Ontario, Canada, 2Muscle Health Research Centre, York University, Toronto,
Ontario, Canada, 3Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Abstract
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease characterized by motor neuron death in the central nervous
system. Vitamin D supplementation increases antioxidant activity, reduces inflammation and improves motor neuron
survival. We have previously demonstrated that vitamin D3 supplementation at 106 the adequate intake improves
functional outcomes in a mouse model of ALS.
Objective: To determine whether vitamin D deficiency influences functional and disease outcomes in a mouse model of
ALS.
Methods: At age 25 d, 102 G93A mice (56 M, 46 F) were divided into two vitamin D3 groups: 1) adequate (AI; 1 IU D3/g feed)
and 2) deficient (DEF; 0.025 IU D3/g feed). At age 113 d, tibialis anterior (TA), quadriceps (quads) and brain were harvested
from 42 mice (22 M and 20 F), whereas the remaining 60 mice (34 M and 26 F) were followed to endpoint.
Results: During disease progression, DEF mice had 25% (P=0.022) lower paw grip endurance AUC and 19% (P=0.017)
lower motor performance AUC vs. AI mice. Prior to disease onset (CS 2), DEF mice had 36% (P=0.016) lower clinical score
(CS) vs. AI mice. DEF mice reached CS 2 six days later vs. AI mice (P=0.004), confirmed by a logrank test which revealed that
DEF mice reached CS 2 at a 43% slower rate vs. AI mice (HR=0.57; 95% CI: 0.38, 1.74; P=0.002). Body weight-adjusted TA
(AI: r=0.662, P=0.001; DEF: r=0.622, P=0.006) and quads (AI: r=0.661, P=0.001; DEF: r=0.768; P,0.001) weights were
strongly correlated with age at CS 2.
Conclusion: Vitamin D3 deficiency improves early disease severity and delays disease onset, but reduces performance in
functional outcomes following disease onset, in the high-copy G93A mouse.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease
characterized by motor neuron atrophy and death in the brain
and spinal cord [1–3]. Symptoms of the disease begin with muscle
weakness, ultimately leading to complete paralysis and death
resulting from respiratory failure [4]. Survival is typically 2–4 years
from diagnosis [5]. To date, Riluzole remains the most effective
pharmaceutical for the treatment of ALS [6]. In clinical studies,
Riluzole improves survival by ,2 months [7], whereas functional
benefits are equivocal [6,8]. Transgenic mice that overexpress the
mutant (G93A) human Cu/Zn-superoxide dismutase gene follow a
similar disease pattern as ALS patients and thus serve as an animal
model for ALS [9]. The pathophysiology of ALS is complex and
includes glutamate excitotoxicity, oxidative stress, inflammation,
mitochondrial dysfunction, protein misfolding and aggregation,
and apoptosis [10].
Several nutrition intervention studies have attempted to
influence one or more pathophysiologies of ALS, as described by
Patel and Hamadeh [10]. In animal models of ALS, anti-
glutamatergic agents such as branched chain amino acids, L-
threonine and magnesium have yielded modest and conflicting
results. However, a delay in disease onset and/or an extended
lifespan was observed for treatments using antioxidants (5–26%
and 4–60%, respectively; Ginkgo biloba, melatonin, lyophilized
red wine, co-enzyme Q10, N-acetyl cysteine, catalase, ginseng,
folic acid and vitamin B12, epigallocatechin gallate, L-carnitine,
vitamin E and trientine plus ascorbate), as well as therapies
targeting mitochondrial dysfunction (7% and 6–17%, respectively;
creatine and pyruvate) and SOD1 stability (8% and 5–10%,
respectively; trientine (alone and with ascorbate) and zinc). Dietary
modifications such as high fat and fast food diets extended lifespan
by 20–22%, however caloric restriction hastened disease onset and
endpoint in the G93A mouse model [11–13].
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exposure to UVB radiation (290–320 nm). Vitamin D is found
naturally in deep ocean fish and fortified in foods such as
margarine, milk and cereals [14–16]. Synthesis of vitamin D3 from
sun exposure is dependent on the zenith angle of the sun, season,
time of day and skin type [17–19]. Vitamin D is best known for its
role in calcium and phosphorous homeostasis, however the
vitamin D receptor (VDR) is present in cells throughout the body
and influences cell proliferation and differentiation as well as
immunomodulation [20]. The VDR has been found in tissues such
as brain [21], spinal cord [22], heart [23], breast [24], pancreas
[25], small intestine [26], and skeletal muscle [27], however there
is controversy in the literature as one recent study has shown that
the VDR is not present in muscle [28]. In addition, the presence of
25-hydroxyvitamin D3-1a-hydroxylase, the enzyme that converts
calcidiol (used to assess vitamin D status) to calcitriol (most active
form of vitamin D) [20], is also present in most tissues in the body
including the brain [29], spinal cord [30], pancreas [29], kidneys
[31], colon [29], lymph nodes [29], skin [29] and smooth muscle
[32].
Vitamin D influences several pathophysiologies of ALS
including glutamate excitotoxicity, oxidative stress, inflammation
and apoptosis. In vitro, Taniura et al [33] pretreated cultured rat
cortical neurons with calcitriol followed by a glutamate insult.
Neuron survival was ,17% higher when treated with 10 nM
calcitriol and ,50% higher with 100 nM compared to a calcitriol-
free control. Vitamin D also reduces oxidative stress and regulates
the inflammatory response by down regulating the expression of
pro-inflammatory cytokines and increasing gene expression of
anti-inflammatory cytokines (i.e. IL-10) [34]. In one study using a
rodent model of diabetes, calcitriol supplementation (5,000 IU/kg
b.wt./d) for 4 wk prior to diabetes induction increased the
antioxidant activity of superoxide dismutase (liver ,2.9 fold and
kidney ,4.2 fold), glutathione peroxidase (liver and kidney ,2.2
fold) and catalase (liver ,2 fold and kidney ,3.5 fold) compared
to diabetic rat controls [35]. In vitro, high levels of calcitriol inhibit
nuclear factor kappa B (NF-kB), a transcription factor which
increases inducible nitric oxide expression, ROS and pro-
inflammatory cytokines such as interleukin-1b (IL-1b), IL-2, IL-
6, IL-8, and tumor necrosis factor-a (TNF-a) [34,36,37]. In vivo,
using a rat model of cortical infarction, 8 day pretreatment with
1 mg/kg/d calcitriol increased glial cell line derived neurotrophic
factor (GDNF) by 2 fold [38] compared to a calcitriol-free control.
GDNF promotes motor neuron survival in vitro [39].
Observational studies have linked low vitamin D status to
neurological, autoimmune and inflammatory diseases that share
some common pathophysiologies with ALS. In one study, men and
women diagnosed with Parkinson’s and Alzheimer’s disease had
14%and 6%lowermeanplasmacalcidiolconcentrationscompared
to controls, respectively (79.8 nmol/L and 87.0 nmol/L vs.
92.5 nmol/L, respectively) [40]. Moreover, 55% of Parkinson’s
disease patients and 41% of Alzheimer’s disease patients had serum
calcidiol #75 nmol/L compared to 36% of controls. In vitro,
calcitriol decreased apoptosis and L-type calcium channel (LVSCC
A1C) mRNA in rat neuronal cultures exposed to amyloid-b (Ab)
[41]. Corrected for control(no Ab or calcitriol added), pretreatment
of calcitriol followed by administration of Ab decreased cytotoxicity
by ,2.5 fold compared to Ab alone at 72 hours. As well, caspase 3
protein was lower in calcitriol-treated cultures exposed to Ab
compared to cultures treated with Ab alone.
IL-10 KO mice, a model of inflammatory bowel disease, given a
vitamin D deficient diet had 41% lower body weight compared to
mice supplemented with calcitriol (0.005 mg/d), indicating severe
tissue wasting. Moreover, after correcting for body weight, vitamin
D deficient mice had 83% heavier small intestines, used as a
measure of disease severity and inflammation, compared to mice
supplemented with calcitriol [42]. Using a mouse model of
arthritis, VDR KO mice had an earlier disease onset and more
severe symptoms of disease [43]. At 9 wk of age, VDR KO mice
had 47% greater grip strength loss, 91% greater paw swelling,
83% higher proteoglycan loss, 35% higher chondrocyte death and
2 fold higher bone erosion compared to controls. Immunohisto-
chemical analysis revealed a 2 fold higher concentration of
synovial macrophages in the hind paws of VDR KO mice
compared to controls.
In a mouse model of multiple sclerosis (experimental autoim-
mune encephalomyelitis; EAE), disease was prevented with an oral
dose of 20 ng/day of calcitriol prior to disease induction, whereas
mice fed a diet devoid of vitamin D followed a typical EAE disease
progression [44]. Calcitriol administered at early signs of overt
EAE symptoms halted disease progression. The effects of calcitriol
were reversible. When calcitriol was removed from the diet, mice
resumed EAE disease progression, reaching a disease severity
equal to mock-treated controls. Pups born from vitamin D
deficient mothers and given a vitamin D deficient diet post-
weaning reached EAE disease onset 43% earlier compared to
offspring supplemented with 20 ng/day of calcitriol [44]. Inter-
estingly, in a different study using the same animal model, pups
born from vitamin D deficient mothers, but given a diet containing
1,500 IU vitamin D3/kg feed beginning at 4 wk of age, had a
delay in disease onset by 17–34% and 61% lower peak disease
severity compared to pups born from vitamin D replete mothers
and fed a diet containing 1,500 IU vitamin D3/kg feed at 4 wk of
age [45]. Also, in the same animal model, second generation
vitamin D deficient mice (fed a diet devoid of vitamin D) had a
delay in disease onset (,49–58%) and lower disease severity (41–
55%) compared to EAE control mice [46].
Human epidemiological studies have linked low vitamin D
intake with type 1 diabetes [47] and low serum calcidiol
concentrations with an elevated risk for cardiovascular disease
[48], atherosclerosis [49], type 2 diabetes [50] and breast cancer
[51]. There is controversy surrounding the optimal vitamin D
dosage as studies have shown a positive [52], negative [53], U-
shaped [54] and no [55] relationship between serum calcidiol and
risk of prostate cancer. Furthermore, one study found a negative
relationship between vitamin D intake and risk of pancreatic
cancer [56], whereas another study found a positive relationship
between serum calcidiol and pancreatic cancer risk [57].
We have previously demonstrated that vitamin D3 supplemen-
tation at 106 the rodent AI attenuates the decline in paw grip
endurance and motor performance in the G93A mouse model of
ALS [58]. We were interested in ascertaining whether dietary
vitamin D3 restriction would reverse these observations in the
same disease model. Hence, the objective of this study was to
investigate the effects of vitamin D deficiency on functional and
disease outcomes, disease onset and lifespan in the G93A mouse
model of ALS.
Methods
Ethics Statement
The study involved the use of rodents. The experimental
protocol strictly followed guidelines put forth by the Canadian
Council of Animal Care and York University Animal Research
Ethics Board. All necessary steps were taken to ameliorate
suffering to animals involved in the study. All procedures were
approved by the York University Animal Research Ethics Board
(protocol # 2007-9).
Vitamin D3 Deficiency in a Mouse Model of ALS
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29354Animals
Male B6SJL-TgN(SOD1-G93A)1Gur hemizygous mice
(No. 002726) were harem-bred with nonaffected female B6SJL
control mice (No. 100012; Jackson Laboratory, Bar Harbor, ME).
Breeding mice consumed Research Diet AIN-93G (1 IU D3/g
feed; Research Diet, New Brunswick, NJ). The presence of the
human G93A transgene was confirmed using polymerase chain
reaction (PCR) amplification of DNA extracted from ear samples
as outlined by Sigma-Aldrich (XNAT REDExtract-N-Amp Tissue
PCR Kit; XNAT-1KT). All animals were housed individually at
age 25 d in a 12 h light/dark cycle.
Study design
One hundred and two G93A mice (46 F, 56 M) were fed a diet
containing an adequate amount of vitamin D3 (1 IU/g feed;
Research DietAIN-93G; Product # D10012G; Research Diets Inc,
New Brunswick, NJ) ad libitum after weaning (21 d) until the study
commenced at age 25 d. At age 25 d, mice were housed in
individual cages and divided into one of two groups: 1) adequate
vitamin D3 (AI; 1 IU D3/g feed; 23 F, 31 M; Research Diet AIN-
93G) and 2) deficient vitamin D3 (DEF; 0.025 IU D3/g feed; 23 F,
25 M; Product # D10030801; Research Diets Inc, New Brunswick,
NJ;Table 1)[59,60]. Ofthese mice, 23 AI (11F,12 M) and 19 DEF
(9 F, 10 M) were sacrificed at age 113 d for tibialis anterior, quadriceps
and brain harvesting, whereas the remaining mice (n=60) were
followed to endpoint. The age of sacrifice (113 d) was based on our
preliminary results showing differences in clinical score (CS)
between DEF and AI mice at age 113 d. For tissue harvesting,
tibialis anterior, quadriceps and brain were weighed immediately after
removal then flash frozen in liquid nitrogen.
When mice attained a CSof 3.0, food and calorie-free gel (Harlan-
Gel, Harlan Teklad, Madison, WI) were placed on the floor of the
cage to fulfill the requirements of the ethics committee. The calorie-
free gel contained synthetic polymers (WATER LOCKH superab-
sorbent polymer G-400, G- 430, G-500, G-530; 95% by weight) and
methanol (4.5% by weight). All measurements were conducted by
two researchers who were blinded to the diets. Following statistical
analysis, researchers were unblinded. Intra-tester coefficients of
variation (CV) were 0.0% for ability to move and 1.2% for clinical
score for researcher #1, and 0.0% for ability to move and 1.1% for
clinical score for researcher #2. The inter-researcher CV are 1.06%
for ability to move and 0.96% for clinical score.
Food intake
Food intake measurements began at age 25 d and were
recorded twice per wk for all mice until endpoint.
Body weight
Beginning at age 25 d, body weight measurements were
recorded twice per wk until mice reached a clinical score of 3.0,
thereafter measurements were recorded daily.
Ability to move
Beginning at age 60 d, ability to move was assessed twice per wk
until mice reached a clinical score of 3.0, thereafter it was assessed
daily. Ability to move followed a 5-point scale: 4=normal
mobility, 3=moving with limited use of the hindlimbs, 2=moving
with the use of the forelimbs, 1=moving only for a short period
with the use of the forelimbs, and 0=not moving.
Paw grip endurance
Beginning at age 60 d, paw grip endurance (PaGE) was
measured 3 times every 10 d (measurement days were separated
by 2–3 days), using the modified hanging wire test [61,62].
Animals were placed on a wire grid held at a height of ,40 cm,
the grid was gently shaken to cause the mouse to fasten its grip on
the wires then inverted. The time was recorded until the mouse
lost its grip, for a maximum score of 180 s. This test was
completed in triplicate, with the highest score used for analysis.
Motor performance
Beginning at age 60 d, motor performance was measured once
every 10 d using the rotarod test (AccuScan Instruments, Inc.,
Columbus, OH). Mice were placed on a rod (30 mm diameter at a
height of 39 cm, covered with corrugated rubber to allow for
traction) that rotated at a gradually increasing speed to 45 rpm
over 60 s and remained at 45 rpm until the mouse could no longer
stay on the rod. The rotarod apparatus was interfaced with a
computer that initiated the test and recorded the competency
score. Motion sensors placed at the bottom of the rotarod chamber
were activated when the mouse fell off the rod and, as a result, the
computer ended the recording session. The test was performed in
triplicate, with the highest score used for analysis.
Clinical score
Beginning at age 60 d, clinical score was assessed daily until
endpoint and followed an 8-point scale based on signs of weakness
exhibited by the mice in order to establish disease severity: 0=no
evidence of disease, 1=shaking or splaying of the hindlimbs when
suspended by the tail (an indication of weakness in the hindlimbs),
1.5=weakness in one hindlimb (compensation for footdrop),
2=weakness in both hindlimbs (change in gait; used as disease
onset when attained on two consecutive days), 2.5=extreme
weakness in one hindlimb (inability to dorsiflex), 3=extreme
weakness in both hindlimbs, 3.5=functional paralysis in one
hindlimb, 4=functional paralysis in both hindlimbs, and
5=mouse cannot right itself within 20 s after being placed on its
side (considered as endpoint) [63]. For all mice, clinical score was
assessed prior to all other functional measurements.
Tibialis anterior, quadriceps and brain
Forty-two G93A mice were sacrificed at age 113 d, whereas the
rest of the mice (n=60) were followed to endpoint. Mice were
Table 1. Macro- and micro-nutrient content of the adequate
intake (AI) vitamin D3 and deficient (DEF) vitamin D3 diets.
Nutrient Diet
AI DEF
Energy (kcal/g) 4 4
Carbohydrate (%) 64 64
Protein (%) 20 20
Fat (%) 7 7
Vitamin D3 (IU/g) 1
a 0.025
b
Calcium (%) 0.5
c 0.5
c
Vitamin mix V10037 (mg/g) 10 0
Vitamin mix V13203 (mg/g) 0 10
Mineral mix S100022G (mg/g) 35 35
Diets provided by Research Diets (AIN-93G; New Brunswick, NJ).
a, included in vitamin mix V10037 [59].
b, included in vitamin mix V13203.
c, included in mineral mix S100022G [60].
doi:10.1371/journal.pone.0029354.t001
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anesthesia as tissues were collected. Tibialis anterior, quadriceps and
brain were removed and immediately weighed.
Statistical analysis
A three-way repeated measures ANOVA (between-subject
factors: diet and sex; within-subject factor: time) was used to
determine significant sex differences over time in food intake, food
intake corrected for body weight, body weight, ability to move,
PaGE, motor performance and clinical score. A two-way repeated
measures ANOVA (between-subject factor: diet; within-subject
factor: time) was used to determine significant differences over
time for ability to move, PaGE, motor performance and clinical
score in four ways: 1) using data from the first day of testing (age
60 d) until the age at which the first group achieved a mean
clinical score of 5 (endpoint; 141 d), 2) using data from the first day
of testing (age 60 d) until the age at which the first group achieved
a mean clinical score of 2 (disease onset; 105 d), 3) using data from
the first day of testing (age 60 d) until age 113 d (age at which 42
mice were harvested for tibialis anterior, quadriceps and brain tissue),
and 4) using data from the age at which the first group achieved a
mean clinical score of 2 (disease onset; 105 d) until the age at
which the first group achieved a mean clinical score of 5 (endpoint;
141 d) (i.e. during disease progression). Statistical analysis of 60–
113 d was chosen to determine if an additional 8 days of data
would influence the results from 60–105 d. Statistical analysis
using data from 60–105 d with and without harvest mice as well as
60–113 d with and without harvest mice were not different,
therefore the results reported are for 60–105 d without harvest
mice; age at CS 2 and CS 4 were included when determining the
effect of diet on age at disease onset and hindlimb paralysis,
respectively. When ANOVA indicated significance, a Newman-
Keuls post-hoc test was used to determine the source of difference.
A Student’s t-test was used to determine significant differences in
disease onset (CS 2), hindlimb paralysis (CS 4), endpoint (CS 5),
number of days between CS 2 to CS 5 (disease progression;
DISPRO), area under the curve (AUC) and cumulative scores
between the diets (within sexes and sexes combined). Statistical
analyses for AUC and cumulative scores for ability to move,
PaGE, motor performance and clinical score were conducted in
three ways: 1) using data from the first day of testing (age 60 d)
until individual endpoint (CS 5) specific for each mouse, 2) using
data from the first day of testing (age 60 d) until individual disease
onset (CS 2) specific for each mouse, and 3) using data from
individual disease onset (CS 2) until individual endpoint (CS 5)
specific for each mouse (i.e. during disease progression). AUC and
cumulative scores for each mouse were corrected for the number
of days between the first day of testing (age 60 d) and endpoint
(first approach), between the first day of testing (age 60 d) and
disease onset (second approach), or between disease onset and
endpoint (third approach, i.e. during disease progression). Analysis
of data between disease onset and endpoint was performed to
specifically investigate the effect of the DEF diet on disease
progression. A logrank test was used to determine differences in
the rate at which the groups reached disease onset, hindlimb
paralysis and endpoint.
The following correlations were performed: ability to move,
PaGE and motor performance vs. CS; PaGE and motor
performance vs. ability to move; as well as motor performance
vs. PaGE. The above correlations were analyzed in four ways: 1) a
three-way repeated measures ANOVA (between-subject factors:
diet and sex; within-subject factor: repeated measures) to identify
sex differences, 2) a two-way repeated measures ANOVA (diet and
repeated measures) to identify diet differences within sex or when
sexes were combined, 3) a two-way ANOVA (diet and sex) to
identify sex differences in AUC and 4) a Student’s t-test to identify
diet differences in AUC within sex or when sexes were combined.
A Student’s t-test was used to determine diet and sex differences
in absolute and body weight-adjusted tibialis anterior, quadriceps and
brain weights. Body weight-adjusted tibialis anterior, quadriceps and
brain weights were correlated with age at CS 2 for each harvest
mouse. Group means for body weight-adjusted tibialis anterior,
quadriceps and brain weights were also correlated with the group
means for age at CS 4 and CS 5, as well as DISPRO, for non-
harvest mice within the same diet and sex. A two-tailed test was
used for all statistical comparisons for outcome measures except
for ability to move, PaGE and motor performance where a one-
tailed test was used, because based on the scientific literature we a
priori hypothesized that vitamin D deficiency would be detrimental
to functional outcomes (ability to move, PaGE and motor
performance). Our lab has recently demonstrated that vitamin
D3 supplementation at 10 fold the AI delays the decline in paw
grip endurance (7%) and motor performance (22%) in the G93A
mouse [58]. Furthermore, a consequence of vitamin D deficiency
is a decrease in the synthesis of the contractile proteins actin and
troponin C [64]. Statistical analyses were performed using
Statistica 6.0 Windows (version 6.0, StatSoft, Tulsa, OK).
Significance was considered at P#0.05, and trends were
considered at 0.05,P#0.10. Data are presented as means 6
standard error of the mean (SEM).
Results
Food intake
AI mice had an average food intake of 3.360.1 g/d
(M=3.460.1 g/d, F=3.260.1 g/d), corresponding to an average
vitamin D3 intake of 3.3 IU/d (M=3.4 IU/d, F=3.2 IU/d)
(Supplemental Figure S1A). DEF mice had an average food intake
of 3.260.1 g/d (M=3.360.1 g/d, F=3.160.1 g/d), correspond-
ing to an average vitamin D3 intake of 0.08 IU/d (M=0.08 IU/d,
F=0.08 IU/d). There were no significant diet- or sex-based
differences for food intake.
AI mice had an average food intake corrected for body weight
of 167.664.1 mg/g b.wt./d (M=155.763.5 mg/g b.wt./d,
F=185.466.0 mg/g b.wt./d) (Supplemental Figure S1B). DEF
mice had an average food intake corrected for body weight of
165.764.1 mg/g b.wt./d (M=153.063.8 mg/g b.wt./d,
F=179.365.5 mg/g b.wt./d). There were no significant diet-
based differences, however males consumed 15% less food
corrected for body weight vs. females (154.463.1 mg/g b.wt./d
vs. 182.463.5 mg/g b.wt./d; P,0.001).
Body weight
AI mice had an average body weight of 20.260.5 g
(M=21.960.4 g, F=17.560.3 g) (Supplemental Figure S1C).
DEF mice had an average body weight of 19.960.5 g
(M=22.160.5 g, F=17.660.2 g). There were no significant
diet-based differences, however males had 25% higher body
weight vs. females (22.060.3 g vs. 17.560.3 g; P,0.001).
Ability to move
There were no significant diet-based differences in ability to
move over time (Supplemental Figure S2A). Between the sexes,
males had 5% (P=0.047) lower ability to move between age 60–
141 d and 15% (P=0.050) lower ability to move during disease
progression vs. females. Over time, ability to move for AI mice was
significantly lower than baseline starting at age 119 d (P,0.001);
starting at 116 d (P=0.049) for males and at 123 d for females
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than baseline starting at age 119 d (P,0.001); starting at 119 d
(P=0.006) for males and at 123 d for females (P,0.001).
Paw grip endurance (PaGE)
There were no significant diet-based differences in PaGE over
time (Supplemental Figure S2B). Between the sexes, males had
13% (P=0.010) lower PaGE between age 60–141 d, as well as
11% (P=0.012) and 23% (P=0.050) lower PaGE prior to disease
onset and during disease progression, respectively, vs. females.
Over time, PaGE for AI mice was significantly lower than baseline
starting at age 97 d (P,0.001); starting at 97 d (P,0.001) for
males and at 100 d for females (P=0.004). For DEF mice, PaGE
was significantly lower than baseline starting at age 100 d
(P=0.006); starting at 103 d (P=0.010) for males and at 100 d
for females (P=0.029). During disease progression, DEF mice had
25% (P=0.022) lower PaGE AUC and 23% (P=0.028) lower
cumulative scores vs. AI mice, mainly due to DEF males having
30% (P=0.039) lower PaGE AUC and 28% (P=0.047) lower
cumulative scores vs. AI males; DEF females had a non-significant
14% lower PaGE AUC and 13% lower cumulative scores vs. AI
females (Figure 1A). Between the sexes, males had 8% (P=0.035)
lower PaGE AUC and 7% (P=0.046) lower cumulative scores
prior to disease onset vs. females.
Motor performance
There were no significant diet-based differences in motor
performance over time (Supplemental Figure S2C). Between the
sexes, males had 18% (P=0.075) lower motor performance during
disease progression vs. females. Over time, motor performance for
AI mice was significantly lower than baseline starting at age 110 d
(P,0.001); starting at 110 d (P,0.001) for males and at 120 d for
females (P,0.001). For DEF mice, motor performance was
significantly lower than baseline starting at age 110 d
(P=0.004); starting at 110 d (P=0.021) for males and at 120 d
for females (P,0.001). During disease progression, DEF mice had
19% (P=0.017) lower motor performance AUC and 18%
(P=0.019) lower cumulative scores vs. AI mice; DEF males had
19% (P=0.073) lower motor performance AUC and 18%
(P=0.077) lower cumulative scores, as well DEF females had
19% (P=0.058) lower motor performance AUC and 18%
(P=0.063) lower cumulative scores, vs. their AI counterparts
(Figure 1B).
Clinical score (CS; disease severity)
Between age 60–141 d, DEF mice had 12% (P=0.029) lower
CS vs. AI mice (Figure 2A), mainly due to DEF males having 14%
(P=0.036) lower CS vs. AI males. Prior to disease onset, DEF
mice had 36% (P=0.016) lower CS vs. AI mice, mainly due to
DEF males having 42% (P=0.026) lower CS vs. AI males; DEF
females had a non-significant 19% lower CS vs. AI females.
Between the sexes, males had 15% (P=0.010) higher CS between
age 60–141 d, as well as 38% (P=0.042) and 11% P=0.030)
higher CS prior to disease onset and during disease progression,
respectively, vs. females. Over time, CS for AI mice was
significantly higher than baseline starting at age 85 d (P=0.006);
starting at 82 d (P=0.030) for males and at 95 d for females
(P=0.015). For DEF mice, CS was significantly higher than
baseline starting at age 96 d (P=0.007); starting at 98 d
(P=0.010) for males and at 98 d for females (P=0.036). Between
age 60 d – CS 5, DEF mice had 14% (P=0.017) lower CS AUC
and 13% (P=0.016) lower cumulative scores vs. AI mice, mainly
due to DEF males having 17% (P=0.039) lower CS AUC and
16% (P=0.037) lower cumulative scores vs. AI males (Figure 2B).
Ability to move vs. CS. DEF mice had 1% (P=0.027) lower
ability to move corrected for CS vs. AI mice, due to DEF females
having 3% (P=0.018) lower ability to move corrected for CS vs.
AI females. There were no significant sex-based differences. For
AI mice, ability to move corrected for CS was significantly lower
than baseline starting at CS 2.25 (P=0.033); starting at CS 2.5
(P,0.001) for males and at CS 2.5 (P=0.026) for females. For
DEF mice, ability to move corrected for CS was significantly lower
than baseline starting at CS 2.5 (P,0.001); starting at CS 2.5
(P=0.003) for males and at CS 2.5 (P=0.001) for females. Data
followed a sigmoidal relationship for males (AI males, r
2=0.999;
DEF males, r
2=0.998; curves were significantly different,
P,0.001) and females (AI females, r
2=0.999; DEF females,
r
2=0.998; curves were significantly different, P,0.001).
PaGE vs. CS. There were no significant diet- or sex-based
differences for PaGE corrected for CS. For AI mice, PaGE
corrected for CS was significantly lower than baseline starting at
CS 1.0 (P=0.012); starting at CS 1.5 (P=0.001) for males and at
CS 1.5 (P=0.002) for females. For DEF mice, PaGE corrected for
CS was significantly lower than baseline starting at CS 1.0
(P=0.019); starting at CS 1.75 (P=0.001) for males and at CS
1.25 (P=0.016) for females. Data followed a sigmoidal
relationship for males (AI males, r
2=0.982; DEF males,
r
2=0.992; curves were not significantly different) and females
(AI females, r
2=0.992; DEF females, r
2=0.994; curves were not
significantly different). During disease progression, DEF mice had
a 27% lower PaGE AUC elevation (P=0.042) for the same CS
AUC vs. AI mice (Figure 3A).
Motor performance vs. CS. DEF mice had 10% (P=0.065)
lower motor performance corrected for CS (Figure 4A) and 9%
(P=0.103) lower motor performance AUC corrected for CS vs. AI
mice (Figure 4B). Diet differences were driven by DEF females
having 11% (P=0.103) lower motor performance corrected for
CS vs. AI females. There were no significant sex-based differences.
For AI mice, motor performance corrected for CS was
significantly lower than baseline starting at CS 0.5 (P=0.038);
starting at CS 1.5 (P=0.013) for males and at CS 0.75 (P=0.006)
for females. For DEF mice, motor performance corrected for CS
was significantly lower than baseline starting at CS 0.5 (P=0.029);
starting at CS 0.75 (P=0.020) for males and at CS 1.0 (P=0.028)
for females. Data followed a sigmoidal relationship for males (AI
males, r
2=0.995; DEF males, r
2=0.993; curves were significantly
different, P,0.001) and females (AI females, r
2=0.975; DEF
females, r
2=0.997; curves were significantly different, P,0.001).
During disease progression, motor performance AUC negatively
correlated with CS AUC for both AI (r=20.359; P=0.047) and
DEF (r=20.404; P=0.030) mice, with DEF mice having 19%
lower motor performance elevation vs. AI mice (P=0.037)
(Figure 3B).
Disease onset
DEF mice reached disease onset (CS 2) six days later vs. AI mice
(10261 d vs. 9661 d; P=0.004). DEF males reached CS 2 five
days later vs. AI males (10062 d vs. 9562 d; P=0.073). Similarly,
DEF females reached CS 2 six days later vs. AI females (10562d
vs. 9962 d; P=0.021). Using the logrank test, DEF mice reached
CS 2 at a 43% slower rate vs. AI mice (HR=0.57; 95% CI: 0.38,
1.74; P=0.002) (Figure 5A). DEF males reached CS 2 at a 33%
slower rate vs. AI males (HR=0.67; 95% CI: 0.35, 1.10;
P=0.101). DEF females reached CS 2 at a 50% slower rate vs.
AI females (HR=0.50; 95% CI: 0.21, 0.80; P=0.009). Between
the sexes, males reached CS 2 five days earlier vs. females (9761d
vs. 10261 d; P=0.005). Using the logrank test, males also reached
CS 2 at a 58% faster rate vs. females (HR=1.58; 95% CI: 1.12,
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faster rate vs. AI females (HR=1.45; 95% CI: 0.87, 2.78;
P=0.069), whereas DEF males reached CS 2 at a 74% faster rate
vs. DEF females (HR=1.74; 95% CI: 1.04, 3.68; P=0.019).
Between 60 d – CS 5, ability to move AUC positively correlated
with age at CS 2 for all mice (r=0.246; P=0.058), with DEF mice
having a 6% delayed disease onset when corrected for ability to
move AUC (P=0.013) vs. AI mice (Supplemental Figure S3A).
Between 60 d – CS 5, PaGE AUC positively correlated with age
at CS 2. DEF mice had a 15% delayed disease onset when
corrected for PaGE AUC vs. AI mice (P=0.007) (Supplemental
Figure S3B), mainly due to DEF males having a 28% higher
elevation vs. AI males (P=0.043). Prior to disease onset, PaGE
AUC positively correlated with age at CS 2. DEF mice had a 16%
delayed disease onset when corrected for PaGE AUC vs. AI mice
(P=0.007), mainly due to DEF males having a 25% higher
elevation vs. AI males (P=0.048).
Hindlimb paralysis and survival
There were no significant differences in the age at hindlimb
paralysis(CS4)between DEF (12862 d) and AI (12562 d) mice,or
between males (12562 d) and females (12862 d). There were no
significant diet-based differences in the rate of reaching CS 4
(Figure 5B). Between the sexes, males reached CS 4 at a 42% faster
rate vs. females (HR=1.42; 95% CI: 0.88, 2.53; P=0.068). In
addition, AI males reached CS 4 at a 69% faster rate vs. AI females
(HR=1.69; 95% CI: 0.88, 4.01; P=0.053), whereas no such
difference was observed between DEF males and DEF females.
Ability to move AUC positively correlated with age at CS 4 for
all mice between 60 d – CS 5 (r=0.441; P,0.001) and during
disease progression (r=0.543; P,0.001). During disease progres-
sion, DEF mice (r=0.607; P=0.001) had a 4% delayed functional
paralysis corrected for ability to move AUC vs. AI mice (r=0.526,
P=0.002) (P=0.054) (Supplemental Figure S3C), mainly due to
DEF males (r=0.526; P=0.044) having a 5% higher elevation vs.
AI males (r=0.615; P=0.005).
There were no significant differences in the age at endpoint (CS
5) between DEF (13262 d) and AI (12961 d) mice. There were
no significant diet-based differences for the rate at reaching CS 5
(Figure 5C). Between the sexes, males reached CS 5 three days
earlier vs. females (12962 d vs. 13262 d; P=0.081). Using the
logrank test, males reached CS 5 at a 44% faster rate vs. females
(HR=1.44; 95% CI: 0.88, 2.58; P=0.067). In addition, AI males
reached CS 5 at an 86% faster rate vs. AI females (HR=1.86;
Figure 1. Paw grip endurance and motor performance AUC during disease progression. (A) Paw grip endurance (PaGE) area under the
curve (AUC) between CS 2–CS 5 (i.e. during disease progression) and (B) motor performance AUC between CS 2–CS 5 for 31 adequate vitamin D3
intake (AI; 1 IU D3/g feed; black squares, 19 males; black circles, 12 females) and 29 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange
squares, 15 males; orange circles, 14 females) G93A mice. (A) During disease progression, DEF mice had 25% (P=0.022) lower PaGE AUC and 23%
(P=0.028) lower cumulative PaGE vs. AI mice, mainly due to DEF males having 30% (P=0.039) lower PaGE AUC and 28% (P=0.047) lower cumulative
PaGE vs. AI males; DEF females had a non-significant 14% lower PaGE AUC and 13% lower cumulative PaGE vs. AI females. (B) During disease
progression, DEF mice had 19% (P=0.017) lower motor performance AUC and 18% (P=0.019) lower cumulative motor performance vs. AI mice. DEF
males had 19% (P=0.073) lower motor performance AUC and 18% (P=0.077) lower cumulative motor performance, as well DEF females had 19%
(P=0.058) lower motor performance AUC and 18% (P=0.063) lower cumulative motor performance, vs. their AI counterparts during disease
progression. Data presented as means 6 SEM. * P=0.039.
doi:10.1371/journal.pone.0029354.g001
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observed between DEF males and DEF females.
Ability to move AUC positively correlated with age at CS 5 for
all mice between 60 d – CS 5 (r=0.224; P=0.085) and during
disease progression (r=0.387; P=0.002).
Disease Progression (DISPRO)
There were no significant differences in DISPRO between DEF
(2662 d) and AI (3062 d) mice. During disease progression,
ability to move AUC positively correlated with DISPRO for all
mice (r=0.525; P,0.001).
Tibialis anterior weights
There were no significant diet-based differences for absolute or
body weight-adjusted tibialis anterior weights (Figure 6A). Between
the sexes, males had 19% heavier absolute tibialis anterior weights
vs. females (P=0.012).
Body weight-adjusted tibialis anterior weights positively correlated
with age at CS 2 for AI (r=0.662; P=0.001) and DEF (r=0.622;
P=0.006) mice (Figure 7A). Per 1 mg/g body weight increase in
tibialis anterior weight, AI and DEF mice experience a 10-d and 8-d
delay in disease onset, respectively. Body weight-adjusted tibialis
anterior weights positively correlated with age at CS 2 for males (AI,
r=0.687, P=0.014; and DEF, r=0.537, P=0.109) and females
(AI, r=0.625, P=0.040; and DEF, r=0.941, P=0.001). Cor-
rected for TA weight, DEF females had a 7% delay in disease
onset vs. AI females (P=0.045).
Quadriceps weights
There were no significant diet-based differences for absolute or
body weight-adjusted quadriceps weights (Figure 6B). Between the
sexes, males had 8% lighter body weight-adjusted quadriceps vs.
females (P=0.094).
Body weight-adjusted quadriceps weights positively correlated
with age at CS 2 for AI (r=0.661; P=0.001) and DEF (r=0.768;
P,0.001) mice. Corrected for quads weight, DEF mice had a 6%
delay in disease onset vs. AI mice (P=0.024) (Figure 7B). Per
1 mg/g body weight increase in quadriceps weight, AI and DEF
mice experience a 3-d and 4-d delay in disease onset, respectively.
Body weight-adjusted quadriceps weights positively correlated with
age at CS 2 for males (AI, r=0.498, P=0.100 and DEF, r=0.850,
P=0.002) and females (AI, r=0.887, P,0.001; and DEF,
r=0.637, P=0.089). Corrected for quads weight, DEF females
had a 6% delay in disease onset vs. AI females (P=0.033).
Figure 2. Clinical score over time and AUC. (A) Clinical score (CS) over time and (B) CS area under the curve (AUC) between age 60 d – CS 5 for
31 adequate vitamin D3 intake (AI; 1 IU D3/g feed; black squares, 19 males; black circles, 12 females) and 29 deficient vitamin D3 intake (DEF; 0.025 IU
D3/g feed; orange squares, 15 males; orange circles, 14 females) G93A mice. (A) Between age 60–141 d, DEF mice had 12% lower CS vs. AI mice
(P=0.029), mainly due to DEF males having 14% lower CS vs. AI males (P=0.036). Between age 60–105 d (i.e. prior to disease onset), DEF mice had
36% lower CS vs. AI mice (P=0.016), mainly due to DEF males having 42% lower CS vs. AI males (P=0.026); DEF females had a non-significant 19%
lower CS vs. AI females. (B) Between age 60 d – CS 5, DEF mice had 14% (P=0.017) lower CS AUC and 13% (P=0.016) lower cumulative CS vs. AI mice,
mainly due to DEF males having 17% (P=0.039) lower CS AUC and 16% (P=0.037) lower cumulative CS vs. AI males. Data presented as means 6 SEM.
doi:10.1371/journal.pone.0029354.g002
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There were no significant diet-based differences for absolute or
body weight-adjusted brain weights (Figure 6C). Between the
sexes, males had 17% lighter body weight-adjusted brain weights
vs. females (P,0.001).
Body weight-adjusted brain weights positively correlated with
age at CS 5 for all mice (r=0.985; P=0.015) (Figure 8). Per 1 mg/
g body weight increase in brain weight, mice experience a 1-d
delay in CS 5.
Discussion
We investigated the effects of vitamin D deficiency, via dietary
vitamin D3 intake equivalent to 2.5% the rodent AI, on functional
and disease outcomes in a mouse model of ALS. DEF mice had
lower PaGE and motor performance AUC following disease onset,
consistent with our previous study showing that vitamin D3
supplementation at 106 the AI attenuates the decline in both
PaGE and motor performance in G93A mice [58]. Surprisingly,
vitamin D deficiency attenuated early disease severity and delayed
disease onset in this high-copy G93A mouse model of ALS.
Following disease onset, DEF mice exhibited compromised
functional capacity, as depicted by lower PaGE, motor perfor-
mance and disease severity-adjusted motor performance com-
pared to AI mice. This is consistent with our previous study
demonstrating that vitamin D3 supplementation at 106 the AI
attenuates the decline in PaGE (7%) and motor performance
(22%) in the same mouse model of ALS [58]. Moreover, using
animal models, vitamin D deficiency affects muscle function in vivo.
Chicks fed a vitamin D3-free diet had 55% lower triceps surae
contractile force compared to control chicks fed ‘‘starter mash’’
(8,000 IU vitamin D3 plus 21.5 g calcium per kg feed) [65].
Providing additional calcium (31 g/kg feed) to the vitamin D3-free
diet increased force of contraction by 48% compared to the
vitamin D3-free diet, albeit remained 33% lower than controls,
indicating a role for vitamin D in skeletal muscle independent of
calcium. In a separate study, chicks initially fed a vitamin D3-free
diet then supplemented with 80 IU/d vitamin D3 showed higher
concentrations of the contractile proteins actin and troponin C
compared to chicks maintained on the vitamin D3-free diet [64].
In addition to compromising the synthesis of contractile protein,
vitamin D deficiency impairs the ability of the sarcoplasmic
reticulum to re-uptake calcium following a muscle contraction
resulting in a delay of muscle relaxation [65,66], and compromis-
ing subsequent muscle contractions and performance [67].
Accordingly, human studies have linked low vitamin D status to
reduced thigh strength [68] and sit-to-stand performance [69]. In
4,100 men and women, subjects in the highest quintile of serum
calcidiol (86–400 nmol/L) had higher sit-to-stand test scores
compared to those in the lowest quintile (9–43 nmol/L) [69]. In
a randomized control trial, 113 institutionalized elderly women
(age, $70 y) supplemented with either a conventional (880 IU/d)
or high (1,600 IU/d) dose of vitamin D3 showed a modest increase
from baseline in dynamic muscle strength (+8% and +5%,
respectively) after 6 mo of supplementation [70]. Although the
authors reported that 60% of the participants had initial serum
calcidiol levels below 50 nmol/L, baseline average serum calcidiol
concentrations were 51.3 nmol/L for the conventional group and
53.6 nmol/L for the high vitamin D3 group. More robust changes
may have been observed had the participants had lower baseline
calcidiol levels. Indeed, whether vitamin D supplementation
conclusively affects muscle function is not clear. A recent meta
analysis of 17 randomized control trials found that patients with
baseline calcidiol levels of #25 nmol/L showed an improvement
in proximal lower limb muscle strength (standard mean differ-
ence=3.52; 95% CI: 2.18, 4.85) following vitamin D supplemen-
tation (cholecalciferol, ergocalciferol, or calcitriol), but not in
adults with calcidiol levels .25 nmol/L [71], indicating that
muscle may be most compromised under vitamin D deficient
Figure 3. Correlations of paw grip endurance and motor
performance vs. clinical score during disease progression. (A)
PaGE AUC between vs. CS AUC and (B) motor performance AUC vs. CS
AUC during disease progression for 31 adequate vitamin D3 intake (AI;
1I UD 3/g feed; black triangles) and 29 deficient vitamin D3 intake (DEF;
0.025 IU D3/g feed; orange triangles) G93A mice. (A) During disease
progression, DEF mice (r=0.213; slope=14.99; P=0.268) had a 27%
lower PaGE AUC elevation (P=0.042) for the same CS AUC vs. AI mice
(r=20.026; slope=23.01; P=0.891). For AI mice: PaGE AUC CS 2–CS
5=(66.05658.23)+[(23.01621.82)6(CS AUC CS 2–CS 5)]. For DEF mice:
PaGE AUC CS 2–CS 5=(3.29635.91)+[(14.99613.27)6(CS AUC CS 2–CS
5)]. (B) During disease progression, motor performance AUC negatively
correlated with CS AUC for both AI (r=20.359; slope=27.13; P=0.047)
and DEF (r=20.404; slope=25.57; P=0.030) mice, with DEF mice
having 19% lower motor performance elevation vs. AI mice (P=0.037).
For AI mice: motor performance AUC CS 2–CS 5=(33.2969.19)
+[(27.1363.45)6(CS AUC CS 2–CS 5)]. For DEF mice: motor perfor-
mance AUC CS 2–CS 5=(26.6266.56)+[(25.5762.42)6(CS AUC CS 2–CS
5)]. Data presented as means 6 SEM.
doi:10.1371/journal.pone.0029354.g003
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status. A recent study found no evidence of the VDR in muscle
[28], hence vitamin D and/or its metabolites may exact their
effects in skeletal muscle through non-genomic pathways.
In vitro, calcitriol is neuroprotective [33,72]. Pretreatment of
cultured rat cortical neurons with 10 nM and 100 nM calcitriol,
followed by a glutamate insult, improves neuron survival by
,17% and ,50%, respectively [33]. The higher dose also
increased VDR mRNA by 3 fold compared to a calcitriol-free
control [33]. In addition, co-administration of calcitriol and
progesterone improved rat neuron survival by 44% compared to
progesterone alone following a glutamate insult [72]. This may be
due to several mechanisms: reduction in L-type voltage sensitive
Ca
2+ channel (LVSCC) activity and LVSCC subunit mRNA, with
a subsequent decrease in the influx of intracellular Ca
2+ via
LVSCCs (a mechanism implicated in neurotoxicity) [73,74];
increase in glial cell line derived neurotrophic factor (GDNF) by
,2 fold [38], promoting motor neuron survival [39]; increases in
nerve growth factor (NGF) mRNA [75] and protein [76],
increasing neuron survival [77,78] and inducing neuronal
proliferation [78,79] and differentiation [80]; increases in neuronal
filament proteins by ,55–80% [microtubule-associated protein 2
(MAP2) and growth associated protein 43 (GAP-43)] and
synaptosomal protein (Synapsin-1) by ,65–90%, promoting
neuronal cell differentiation and maturation [33].
Paradoxically, dietary vitamin D3 restriction mitigated early
disease severity and delayed disease onset. In contrast to the
present study, in a mouse model of multiple sclerosis (EAE), mice
fed a vitamin D3-free diet reached disease onset 43% earlier
compared to mice fed a diet supplemented with 20 ng/d of
calcitriol [44]. Pregnant mothers were fed a diet devoid of vitamin
D beginning two weeks into pregnancy and the offspring were
Figure 4. Correlations of motor performance vs. clinical score. (A) motor performance (s) vs. CS and (B) motor performance vs. CS area under
the curve (AUC) for 31 adequate vitamin D3 intake (AI; 1 IU D3/g feed; black squares, 19 males; black circles, 12 females) and 29 deficient vitamin D3
intake (DEF; 0.025 IU D3/g feed; orange squares, 15 males; orange circles, 14 females) G93A mice. (A) DEF mice had 10% lower motor performance
corrected for CS vs. AI mice (P=0.065). (B) DEF mice had 9% lower motor performance AUC corrected for CS vs. AI mice (P=0.103). Diet differences
were driven by DEF females having 11% lower motor performance corrected for CS vs. AI females (P=0.103). Data presented as means 6 SEM.
doi:10.1371/journal.pone.0029354.g004
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intake (AI; 1 IU D3/g feed; black squares, 31 males; black circles, 23 females) and 47 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange
squares, 25 males; orange circles, 22 females) G93A mice, (B) probability of hindlimb paralysis (CS 4; %) for 32 AI (black squares, 19 males; black circles,
13 females) and 31 DEF (orange squares, 17 males; orange circles, 14 females) G93A mice and (C) probability of survival (CS 5; %) for 31 AI (black
squares, 19 males; black circles, 12 females) and 29 DEF (orange squares, 15 males; orange circles, 14 females) G93A mice. (A) DEF mice reached CS 2
at a 43% slower rate vs. AI mice (HR=0.57; 95% CI: 0.38, 1.74; P=0.002). DEF males reached CS 2 at a 33% slower rate vs. AI males (HR=0.67; 95% CI:
0.35, 1.10; P=0.101). DEF females reached CS 2 at a 50% slower rate vs. AI females (HR=0.50; 95% CI: 0.21, 0.80; P=0.009). (B and C) There were no
significant diet-based differences in the rate at reaching CS 4 or CS 5.
doi:10.1371/journal.pone.0029354.g005
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calcitriol-supplemented diet at weaning. Weanling offspring given
the vitamin D-free diet were predisposed to vitamin D deficiency,
as reflected through their very low serum calcitriol concentrations
(,13–34 pmol/L) compared to the calcitriol-supplemented off-
spring (99–169 pmol/L) at 6 wk of age. Conversely, using the
same EAE mouse model, Fernandes de Abreu et al [45] as well as
Deluca and Plum [46] found that vitamin D deficiency delays
disease onset and lowers disease severity compared to EAE
controls. In the Fernandes de Abreu et al study, there was a
significant delay in disease onset (17–34%) and lower peak disease
severity (61%) in offspring born to mothers consuming a normo-
calcemic vitamin D3-free diet but were themselves placed on the
control diet following birth, as compared to control mice (both
mother and offspring fed the control diet containing 1,500 IU
vitamin D3/kg feed) [45]. The authors concluded that the vitamin
D deficient environment during gestation induced higher sensitiv-
ity to vitamin D in pups, as evidenced by an upregulation of VDR
mRNA at birth by ,3.7 fold. The subsequent switch to a normal
diet upon birth was akin to supplementing control mice with high
doses of vitamin D3, hence resulting in the observed changes in
disease onset, disease severity and immune response (66% lower
TNF-a mRNA at 30 d post-immunization vs. controls). The
mechanisms proposed by the authors center around an upregula-
tion of the VDR, however we propose a simpler mechanism
explaining the observed attenuation in disease severity prior to CS
2 and delay in disease onset in the DEF mice in the present study.
Following dietary vitamin D3 restriction, serum calcidiol concen-
trations would gradually decrease over time to well below those in
the control group, with a concomitant compensatory increase in
serum calcitriol concentrations. This is supported by studies
showing greater serum calcitriol concentrations in rodents with
insufficient dietary intake of vitamin D3 or suboptimal serum
calcidiol [81–83]. However, under prolonged dietary vitamin D3
restriction or severely compromised vitamin D status, physiological
stores of vitamin D3 would be exhausted [81,83], as reflected by
calcidiol concentrations too low to maintain high calcitriol levels
even in the presence of a combination of enhanced calcitriol
synthesis (CYP27B1) together with reduced calcitriol breakdown
(CYP24A1) [81]. Based on this, supranormal calcitriol concentra-
Figure 6. Body weight-adjusted tibialis anterior, quadriceps and brain weights. Body weight-adjusted (mg/g b.wt.) (A) tibialis anterior, (B)
quadriceps and (C) brain weights for 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; black squares, 12 males and 11 females) and 19 deficient
vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange squares, 10 males and 9 females) G93A mice. (A, B and C) There were no significant diet-based
differences in body weight-adjusted tibialis anterior, quadriceps or brain weights. Data presented as means 6 SEM.
doi:10.1371/journal.pone.0029354.g006
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predicated on both the half-life of calcidiol and calcitriol clearance
[81,84], with a subsequent precipitous decline in calcitriol upon
exhaustion of vitamin D3 stores and circulating calcidiol as
evidenced by the enhanced rate of increase in CS peri- and post-
disease onset (age, $90 d; Figure 2A). This is corroborated by
Fleet et al [81] demonstrating that mice consuming 0.050 IU D3/
g feed diet had serum calcidiol levels ,23% those on 1 IU D3/g
feed diet (equivalent to the AI diet in the current study), and those
consuming 0.025 IU D3/g feed diet (equivalent to the DEF diet in
the current study) had serum calcitriol levels less than 50% those
on the AI diet following 11 wk of dietary intervention (age, 98 d)
[81]. If this is the case, why did DEF mice not exhibit improved
functional outcomes compared to AI mice? Calcitriol is the most
active form of vitamin D and possesses neuroprotective properties
[33,72]. Calcidiol has some similar, but less robust, physiological
and cellular roles contingent upon specific tissues, and induces
gene expression separate from calcitriol [85]. Taken together, we
hypothesize that in the presence of low calcidiol the supranormal
concentrations of calcitriol rescued the muscle from declining in
function, but the subsequent severe vitamin D deficient environ-
ment peri- and post-CS 2 compromised muscle function. The
compensatory increase in calcitriol pre-disease onset may have also
improved immune function. In vitro, calcitriol has shown to
moderate levels of ROS, NF-kB, IL-1b, IL-2, IL-6, IL-8, and
TNF-a [34,36,37]. Moreover, calcitriol activates T cells which
have neuroprotective effects and slow disease progression in an
animal model of ALS [86–88]. Post-disease onset, however, the
immune system would be deprived of the anti-oxidant effects of
calcitriol. This is corroborated by our previous observation that
vitamin D3 supplementation at 106the AI attenuated the decline
in both PaGE and motor performance in the G93A mouse model
of ALS [58]. Based on this, we hypothesize that both calcidiol and
calcitriol have tissue-specific functions [85,89].
Between the sexes, males had lower ability to move, PaGE and
motor performance compared to females. Males also had a higher
clinical score and hastened disease onset, hindlimb paralysis and
endpoint compared to females. Interestingly, vitamin D deficiency
Figure 7. Correlation of disease onset vs. body weight-adjusted tibialis anterior and quadriceps weights. Age at disease onset (CS 2; d) vs.
body weight-adjusted (mg/g b.wt.) (A) tibialis anterior weight and (B) quadriceps weight for 23 adequate vitamin D3 intake (AI; 1 IU D3/g feed; black
triangles, AI mice; black squares, 12 males; black circles, 11 females) and 18 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange triangles, DEF
mice; orange squares, 10 males; orange circles, 8 females) G93A mice. (A) Body weight-adjusted tibialis anterior weights positively correlated with age
at CS 2 for AI (r=0.662; slope=10.05; P=0.001) and DEF mice (r=0.622; slope=8.21; P=0.006). DEF females had a 7% delay in reaching disease onset
corrected for TA weight (P=0.045) vs. AI females. For AI mice: Age at CS 2 (d)=(62.4767.67)+[(10.0562.49)6(tibialis anterior weight (mg/g b.wt.))].
For DEF mice: Age at CS 2 (d)=(70.9668.37)+[(8.2162.58)6(tibialis anterior weight (mg/g b.wt.))]. (B) Body weight-adjusted quadriceps weights
positively correlated with age at CS 2 for AI (r=0.661; slope=2.74; P=0.001) and DEF (r=0.768; slope=4.02; P,0.001) mice; DEF mice had a 6% delay
in reaching disease onset corrected for quads weight (P=0.024) vs. AI mice. For AI mice: Age at CS 2 (d)=(63.7467.36)+[(2.7460.68)6(quadriceps
weight (mg/g b.wt.))]. For DEF mice: Age at CS 2 (d)=(55.5768.76)+[(4.0260.84)6(quadriceps weight (mg/g b.wt.))]. Data presented as means 6 SEM.
doi:10.1371/journal.pone.0029354.g007
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5 at a faster rate compared to AI females, whereas no such
difference was observed between DEF males and DEF females. In
addition, males were more responsive to vitamin D deficiency; diet
differences were mainly driven by DEF males having significantly
lower PaGE following disease onset and lower early disease
severity. Females were more resistant to a sharp reduction in
vitamin D3 intake, possibly due to the interaction between
estrogen and vitamin D metabolites. In a mouse model of EAE,
female mice supplemented with vitamin D3 (40 IU/d) had 67%
higher calcitriol, 75% lower calcitriol-deactivating enzyme
CYP24A1 mRNA, and 65% higher CYP27B1: CYP24A1 mRNA
ratio (enzyme transcript ratio coding for calcitriol synthesis:deacti-
vation) in the spinal cord compared to supplemented males [30].
The ability of females to synthesize more calcitriol in the CNS
compared to males may have predisposed the G93A females to
relatively higher basal CNS calcitriol, levels attained by the G93A
males, albeit transiently, only under vitamin D deficiency.
Accordingly, as vitamin D3 intake decreases below 0.40 IU D3/
g feed, CYP24A1 mRNA decreases, and at very low levels of
vitamin D3 intake (below 0.05 IU D3/g feed) CYP27B1 mRNA
increases [81]. It is possible that restricting dietary vitamin D3 may
not effect significant increases in CNS calcitriol in females above
their heightened basal levels.
During disease progression, ability to move was positively
correlated with age at hindlimb paralysis. As well, both AI and
DEF mice had positive correlations between body weight-adjusted
tibialis anterior and quadriceps weights with age at CS 2, indicating
that improvements in muscle mass and function may delay disease
onset and paralysis. This is corroborated by previous research
showing that G93A mice supplemented with 2% creatine
monohydrate (CrM) had 25% greater extensor digitorum longus
weight (mg/g b.wt.) [90] and a significant 7% delay in disease
onset (,12 d) compared to non-supplemented G93A mice [91].
Furthermore, supplementing human ALS patients with 20 g/d of
CrM for 7 d increased maximal voluntary isometric muscular
contraction in knee extensors (70%) and elbow flexors (53%)
compared to pre-treatment values [92]. These results emphasize
the need for clinicians to focus on increasing muscle mass and
function of ALS patients to improve prognosis.
In spite of some limitations, the underlying pathophysiologies
common to both the G93A mouse model and ALS patients makes
extrapolating to humans plausible [5,9]. At 25 d of age, when
dietary intervention commenced, G93A mice did not exhibit the
ALS phenotype. As well, the first mean group disease onset was
reached 70 d following commencement of intervention (at 95 d of
age). In contrast, the time period between the first appearance of
ALS symptoms and clinical diagnosis varies widely in ALS
patients, ranging between 6–38 mo [93–95]. Accordingly, ALS
patients are prescribed nutritional or pharmaceutical therapeutics
well after the initiation of overt signs and symptoms, when CNS
damage has become irreversible. Would manipulating dietary
vitamin D3 intake in ALS patients improve prognosis? There is a
dearth of information on the vitamin D status of ALS patients.
One study found that serum calcitriol was in the low-normal range
(29–65 pmol/l), but did not report serum calcidiol [96]. The
observed attenuation in disease severity and delayed disease onset
in DEF mice in the present study may be counterintuitive.
Physiologically, these improvements in disease outcomes coincide
with the adaptive compensatory increase in calcitriol simultaneous
with reductions in calcidiol following dietary vitamin D3 restriction
[81]. In evidence, DEF mice exhibited compromised functional
capacity following disease onset, congruent with exhausted stores
of endogenous vitamin D3 and diminished synthesis of calcidiol
and calcitriol, predicated on the half-lives of calcidiol and calcitriol
as well as the accelerated progress of disease and short life span
characteristic of this high-copy G93A mouse model. Furthermore,
dietary vitamin D3 at 10 fold the AI improves functional capacity
in the same mouse model [58]. To address the current gaps in our
understanding, future studies should: ascertain the effects of
prolonged vitamin D deficiency on functional and disease
outcomes in the low-copy G93A mouse model of ALS, a model
with a disease onset of 195–205 d and lifespan of 237–250 d of age
[97–99]; measure the temporal changes in serum, skeletal muscle
and CNS vitamin D metabolites (specifically, calcidiol and
calcitriol) following dietary vitamin D3 restriction in G93A rodent
models; investigate the use of calcitriol as a treatment in G93A
mice; and provide rodent models of ALS with vitamin D deficient
and supplemented diets concurrent with disease onset.
In conclusion, the present study demonstrates that vitamin D
deficiency differentially affects functional and disease outcomes.
Dietary vitamin D3 restriction (0.025 IU/g feed) decreases PaGE
and motor performance, improves early disease severity and delays
disease onset compared to a diet with adequate vitamin D3 (1 IU/
g feed) in the high-copy G93A mouse model of ALS. We
hypothesize that the attenuation of early disease severity and the
delay in disease onset may have been due to a transient
compensatory increase in calcitriol under conditions of decreasing
calcidiol concentrations, whereas the reduced functional perfor-
mance may be due to changes in intramuscular calcium regulation
and a decrease in contractile protein synthesis. Based on in vitro
[100] and in vivo studies [85,89], we hypothesize that our results
may also suggest a possible tissue-specific effect of vitamin D and
its metabolites in the CNS as compared with skeletal muscle.
Further research in this animal model is needed prior to
Figure 8. Correlation of group body weight-adjusted brain
weights vs. group age at endpoint. The average group body
weight-adjusted brain weights (mg/g b.wt.) for 23 adequate vitamin D3
intake (AI; 1 IU D3/g feed; black squares, 12 males; black circles, 11
females) and 19 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed;
orange squares, 10 males; orange circles, 9 females) vs. the average
group age at endpoint (CS 5; d) for 31 AI (19 males and 12 females) and
29 DEF (15 males and 14 females) G93A mice. Body weight-adjusted
brain weights positively correlated with age at CS 5 for all mice
(r=0.985; slope=1.32; P=0.015). Age at CS 5 (d)=(103.8063.19)
+[(1.3260.16)6(brain weights (mg/g b.wt.))]. Data presented as means
6 SEM.
doi:10.1371/journal.pone.0029354.g008
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responsible for the observed improvement in early disease severity
and delay in disease onset may help deliver novel therapies to ALS
patients.
Supporting Information
Figure S1 Food intake, food intake corrected for body
weight and body weight over time. (A) Food intake (g), (B)
food intake corrected for body weight (mg/g b.wt./d) and (C) body
weight (g) for 31 adequate vitamin D3 intake (AI; 1 IU D3/g feed;
black squares, 19 males; black circles, 12 females) and 29 deficient
vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange squares, 15
males; orange circles, 14 females) G93A mice. (A, B and C) There
were no significant diet-based differences in food intake, food
intake corrected for body weight or body weight over time. Data
presented as means 6 SEM.
(TIF)
Figure S2 Ability to move, paw grip endurance and
motor performance over time. (A) Ability to move, (B) Paw
grip endurance (PaGE; s) and (C) motor performance (s) over time
for 31 adequate vitamin D3 intake (AI; 1 IU D3/g feed; black
squares, 19 males; black circles, 12 females) and 29 deficient
vitamin D3 intake (DEF; 0.025 IU D3/g feed; orange squares, 15
males; orange circles, 14 females) G93A mice. (A, B and C) There
were no significant diet-based differences in ability to move, PaGE
or motor performance over time. Data presented as means 6
SEM.
(TIF)
Figure S3 Correlations of disease and functional out-
comes. Age at disease onset (CS 2; d) vs. (A) Ability to move area
under the curve (AUC) and (B) paw grip endurance (PaGE) AUC
between age 60 d – CS 5, and (C) age at hindlimb paralysis (CS 4;
d) vs. ability to move AUC during disease progression for 31
adequate vitamin D3 intake (AI; 1 IU D3/g feed; black triangles)
and 29 deficient vitamin D3 intake (DEF; 0.025 IU D3/g feed;
orange triangles) G93A mice. (A) Between 60 d – CS 5, DEF mice
(r=0.185; slope=16.12; P=0.338) had a 6% delayed disease
onset when corrected for ability to move AUC (P=0.013) vs. AI
mice (r=0.229; slope=19.02; P=0.215). (B) Between 60 d – CS
5, DEF mice (r=0.311; slope=0.087; P=0.100) had a 15%
delayed disease onset when corrected for PaGE AUC (P=0.007)
vs. AI mice (r=0.175; slope=0.067; P=0.347), mainly due to
DEF males (r=0.375; slope=0.087; P=0.169) having a 28%
higher elevation (P=0.043) vs. AI males (r=0.092; slope=0.031;
P=0.708). (C) During disease progression, DEF mice (r=0.607;
slope=21.76; P=0.001) had a 4% delayed functional paralysis
corrected for ability to move AUC (P=0.054) vs. AI mice
(r=0.526, slope=13.48; P=0.002), mainly due to DEF males
(r=0.526; slope=20.55; P=0.044) having a 5% higher elevation
(P=0.104) vs. AI males (r=0.615; slope=15.09; P=0.005). Data
presented as means 6 SEM.
(TIF)
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